Welcome to our dedicated page for uniQure N.V. SEC filings (Ticker: QURE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on uniQure N.V.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into uniQure N.V.'s regulatory disclosures and financial reporting.
Jack Kaye submitted a Form 144 reporting proposed sales of 21,167 Ordinary Shares on 06/30/2026, citing a stock option exercise pursuant to a 10b5-1 plan with cash proceeds. The filing lists three recent dispositions in June 2026 totaling 9,933 shares sold for cash.
uniQure N.V. CEO and Managing Director Matthew C. Kapusta reported option exercises and share sales in Ordinary Shares. On June 24–25, 2026, he exercised stock options to acquire 32,844 shares at $31.71 per share and sold 35,412 shares in open-market transactions around $50 per share. The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on October 5, 2025. Following these transactions, he directly holds 519,227 Ordinary Shares.
UniQure N.V. reports proposed sale of 22,402 ordinary shares under vesting Restricted Stock Units, with an intended sale date of 06/26/2026. The filing also discloses a prior disposition of 45,000 ordinary shares by Walid Abi-Saab on 05/08/2026 for $1,127,435.50.
The 22,402 shares are tied to RSU vesting for services rendered; the filing lists Citigroup Global Markets, Inc. as a broker on the form. Timing and cash‑flow treatment for the new sale are those stated on the form.
Kapusta Matthew C reported a proposed sale of 28,716 ordinary shares of uniQure N.V. on 06/25/2026 via a stock option exercise and sale for cash.
The filing also lists recent sales by Kapusta in the prior three months, including 152,844 shares for $6,724,136.05 on 06/17/2026 and additional transactions on 06/18/2026 and 06/24/2026.
uniQure N.V. has priced an underwritten public offering of 4,945,055 ordinary shares at $45.50 per share, for expected gross proceeds of about $225 million. Underwriters exercised a 30-day option in full to buy an additional 741,758 shares at the same public price, less underwriting discounts and commissions.
The company estimates net proceeds from the offering of approximately $242.7 million after fees and expenses. The shares are being issued under an automatically effective Form S-3ASR shelf registration, with closing expected on or about June 25, 2026, subject to customary conditions.
uniQure N.V. is conducting a primary offering of 4,945,055 ordinary shares at a public offering price of $45.50 per share, for aggregate gross proceeds of $225,000,003. Underwriting discounts total $13,500,000, with estimated proceeds to uniQure before expenses of $211,500,003. Delivery is expected on June 25, 2026.
The underwriters have a 30-day option to purchase up to an additional 741,758 ordinary shares. After the offering (no exercise of the option), ordinary shares outstanding would be 67,978,304 (or 68,720,062 if the option is fully exercised). Proceeds are intended to fund commercialization readiness and potential launches for AMT-130, a confirmatory study for AMT-130, development of other clinical candidates, business development and general corporate purposes.
uniQure reports a Rule 144 notice to sell ordinary shares. The filing lists brokered sales activity and planned dispositions tied to vested PSUs/RSUs and option exercises. The filing shows multiple past sales by Matthew C. Kapusta on 06/17/2026 and 06/18/2026.
uniQure N.V. is offering $150,000,000 of ordinary shares and pre-funded warrants pursuant to a preliminary prospectus supplement dated June 22, 2026. The offering includes ordinary shares and, in lieu of shares to certain investors, pre-funded warrants exercisable at $0.0001 per share. Proceeds are intended to fund commercialization readiness and a confirmatory study for AMT-130, development of other clinical candidates, business development and general corporate purposes. The supplement summarizes recent clinical and regulatory developments for AMT-130, AMT-260 and AMT-191, including a three-year Phase I/II analysis for AMT-130 and planned BLA and UK MAA submissions in Q3 2026.
uniQure N.V.’s CEO and Managing Director Matthew C. Kapusta reported a combination of share sales and option exercises in uniQure N.V. ordinary shares. On June 17–18, 2026, he sold an aggregate of 206,100 ordinary shares in multiple open‑market transactions and exercised stock options covering 67,237 ordinary shares.
Sale prices were reported as weighted averages, with underlying trades occurring in ranges disclosed in the footnotes. The filing states these transactions were carried out under a Rule 10b5‑1 sales plan adopted on October 5, 2025. Following the transactions, Kapusta directly owned 521,795 ordinary shares, and the derivative section in this filing shows no remaining stock options related to these exercises.
uniQure N.V. director Balachandran Madhavan reported an exercise-and-sell transaction in Ordinary Shares. On June 17, 2026, he exercised stock options for 11,685 shares at strike prices of $19.39 and $31.71 per share.
The same total of 11,685 shares was then sold in open-market transactions at weighted average prices of $42.60, $43.66, and $47.08 per share. The filing states that the sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on March 10, 2026.